RecruitingPhase 1NCT07401875
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Sponsor
M.D. Anderson Cancer Center
Enrollment
35 participants
Start Date
Mar 24, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called HC-7366, a drug called Nivolumab, and others for people with hc-7366, kidney cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNivolumab
Given by IV
DRUGHC-7366
Given by po
DRUGipilimumab
Given by IV
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07401875
Related Trials
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
NCT000507521 location
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
NCT000331371 location
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
NCT061380672 locations
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT000268841 location
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
NCT000012381 location